Abstract PS3-11-11: A comparative study of trastuzumab and pertuzumab combination subcutaneous and intravenous infusion in patients with HER2-positive breast cancer: a retrospective and prospective combined study of time efficiency, cost-effectiveness, quality of life, and socioeconomic impact